RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation boosts cancer drug in Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests whether adding low-dose radiation to the drug elranatamab can better kill cancer cells in people with multiple myeloma that has come back or not responded to treatment and has spread outside the bone. About 34 adults will receive the combination. The goal is to s…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study tests two drugs—mezigdomide (a pill) and talquetamab (an injection)—in people with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to find a safe dose and schedule. About 25 participants will receive the drugs…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for myeloma patients: epunamin combo under study
Disease control Recruiting nowThis study is testing whether adding the drug epunamin to a standard chemotherapy regimen (DECP) can help people with relapsed or refractory multiple myeloma, a type of blood cancer that has not responded to previous treatments. The study will enroll 48 adults aged 18 to 75 and t…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Shanxi Bethune Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug duo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests two drugs, elranatamab and isatuximab, given as shots under the skin for people with multiple myeloma that has returned or not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors and control the disease. About 30 pa…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for myeloma: experimental drug faces off against standard combo in major trial
Disease control Recruiting nowThis phase 3 study tests a new drug, linvoseltamab, against a standard three-drug combo (EPd) in people with multiple myeloma that has returned after 1-4 prior treatments. About 410 adults will be randomly assigned to receive either linvoseltamab or EPd. The goal is to see which …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a combination of two drugs, mezigdomide and elranatamab, in 75 people with relapsed or refractory multiple myeloma (a blood cancer that has come back or stopped responding to treatment). The goal is to see how well the combination works and how safe it is. Partic…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New strategy aims to shield myeloma patients from dangerous virus during treatment
Disease control Recruiting nowThis study is testing whether the antiviral drug letermovir can prevent a common and serious viral infection called CMV in people with relapsed/refractory multiple myeloma who are receiving the immunotherapy elranatamab. The trial will enroll 40 adults who are CMV-positive. Resea…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Real-World data on new myeloma drugs: how well do they work outside trials?
Knowledge-focused Recruiting nowThis study collects information from about 900 people with relapsed/refractory multiple myeloma who received teclistamab or talquetamab in regular medical practice, not in a clinical trial. Researchers will look at how well the drugs work, how long benefits last, and what side ef…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC